MOR Stock Price, Chart, Stats & News

Headquartered in Planegg, Germany, and founded in 1992, MorphoSys AG is a commercial-stage biopharmaceutical firm dedicated to the innovation, advancement, and market launch of therapeutic antibodies. The company's primary mission is to provide novel treatments for patients battling cancer and autoimmune diseases, serving markets in the United States and through global collaborations. MorphoSys's flagship commercial product is Tafasitamab, an antibody therapy specifically indicated for the treatment of various B-cell malignancies, such as diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.